FLGT vs. CPRX
FLGT (Fulgent Genetics, Inc.) and CPRX (Catalyst Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — FLGT in Diagnostics & Research, CPRX in Biotechnology. Over the past 5 years, FLGT returned -29.08%/yr vs 41.46%/yr for CPRX. Their 0.20 correlation means their historical movements had little consistent relationship.
Performance
FLGT vs. CPRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, FLGT achieves a -37.00% return, which is significantly lower than CPRX's 34.92% return.
FLGT
- 1D
- -18.11%
- 1M
- -20.62%
- 6M
- -36.83%
- YTD
- -37.00%
- 1Y
- -10.69%
- 3Y*
- -24.74%
- 5Y*
- -29.08%
- 10Y*
- —
- ALL TIME*
- 6.14%
CPRX
- 1D
- 0.00%
- 1M
- 0.13%
- 6M
- 29.59%
- YTD
- 34.92%
- 1Y
- 49.10%
- 3Y*
- 32.72%
- 5Y*
- 41.46%
- 10Y*
- 44.91%
- ALL TIME*
- 8.79%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $6.50M | $5.58M | $7.39M |
FLGT vs. CPRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
FLGT Fulgent Genetics, Inc. | -37.00% | 42.23% | -36.11% | -2.92% | -70.39% | 93.07% | 303.88% | 306.94% | -27.63% | -62.14% |
CPRX Catalyst Pharmaceuticals, Inc. | 34.92% | 11.84% | 24.15% | -9.62% | 174.74% | 102.69% | -10.93% | 95.31% | -50.90% | 272.38% |
Correlation
The correlation between FLGT and CPRX is 0.20, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.20 |
Correlation (3Y) Balances recent behavior with more history. | 0.26 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.29 |
Correlation (All Time) Calculated using the full available price history since Sep 29, 2016 | 0.20 |
Fundamentals
FLGT:
$470.03M
CPRX:
$3.85B
FLGT:
-$2.80
CPRX:
$1.74
FLGT:
1.54
CPRX:
6.70
FLGT:
0.46
CPRX:
3.95
FLGT:
$323.93M
CPRX:
$596.96M
FLGT:
$115.26M
CPRX:
$378.23M
FLGT:
-$72.79M
CPRX:
$313.50M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
FLGT vs. CPRX — Risk / Return Rank
FLGT
CPRX
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
FLGT vs. CPRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Fulgent Genetics, Inc. (FLGT) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| FLGT | CPRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.60 | ||
| Sortino ratioReturn per unit of downside risk | -1.79 | ||
| Omega ratioGain probability vs. loss probability | 1.07 | 1.31 | -0.24 |
| Calmar ratioReturn relative to maximum drawdown | -0.07 | 3.52 | -3.58 |
| Martin ratioReturn relative to average drawdown | -0.12 | 9.42 | -9.54 |
Loading charts...
Drawdowns
FLGT vs. CPRX - Drawdown Comparison
The maximum FLGT drawdown since its inception was -92.50%, roughly equal to the maximum CPRX drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for FLGT and CPRX.
Loading charts...
Drawdown Indicators
| FLGT | CPRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.50% | -94.25% | +1.75% |
Max Drawdown (1Y)Largest decline over 1 year | -55.30% | -13.91% | -41.39% |
Max Drawdown (3Y)Largest decline over 3 years | -64.54% | -27.29% | -37.25% |
Max Drawdown (5Y)Largest decline over 5 years | -87.56% | -45.37% | -42.19% |
Max Drawdown (10Y)Largest decline over 10 years | — | -64.87% | — |
Current DrawdownCurrent decline from peak | -91.00% | -0.03% | -90.97% |
Average DrawdownAverage peak-to-trough decline | -61.99% | -51.73% | -10.26% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 30.18% | 5.18% | +25.00% |
Volatility
FLGT vs. CPRX - Volatility Comparison
Fulgent Genetics, Inc. (FLGT) has a higher volatility of 21.41% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 0.41%. This indicates that FLGT's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| FLGT | CPRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 21.41% | 0.41% | +21.00% |
Volatility (6M)Calculated over the trailing 6-month period | 60.11% | 21.80% | +38.31% |
Volatility (1Y)Calculated over the trailing 1-year period | 60.38% | 31.77% | +28.61% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 50.92% | 47.65% | +3.27% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 75.46% | 59.86% | +15.60% |
Dividends
FLGT vs. CPRX - Dividend Comparison
Neither FLGT nor CPRX has paid dividends to shareholders.
Financials
FLGT vs. CPRX - Financials Comparison
This section allows you to compare key financial metrics between Fulgent Genetics, Inc. and Catalyst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
FLGT vs. CPRX - Profitability Comparison
FLGT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Fulgent Genetics, Inc. reported a gross profit of 25.68M and revenue of 85.39M. Therefore, the gross margin over that period was 30.1%.
CPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.
FLGT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Fulgent Genetics, Inc. reported an operating income of -29.72M and revenue of 85.39M, resulting in an operating margin of -34.8%.
CPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.
FLGT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Fulgent Genetics, Inc. reported a net income of -29.53M and revenue of 85.39M, resulting in a net margin of -34.6%.
CPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.
Frequently Asked Questions
FLGT and CPRX have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
FLGT has higher volatility (21.41%) compared to CPRX (0.41%). In terms of maximum drawdown, FLGT dropped -92.50% vs CPRX's -94.25%.
CPRX currently has the higher Sharpe Ratio (1.54 vs -0.06), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for FLGT and CPRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer